Pembrolizumab + Cisplatin + Carboplatin + Gemcitabine
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Conditions
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Trial Timeline
Sep 22, 2022 → Dec 1, 2028
NCT ID
NCT05286619About Pembrolizumab + Cisplatin + Carboplatin + Gemcitabine
Pembrolizumab + Cisplatin + Carboplatin + Gemcitabine is a phase 2 stage product being developed by Merck for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05286619. Target conditions include Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05286619 | Phase 2 | Recruiting |
| NCT02853305 | Phase 3 | Completed |
Competing Products
4 competing products in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Drug Combination Therapy | Sun Pharmaceutical | Phase 2 | 52 |
| MEDI4736 + Tremelimumab + MEDI4736 + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| pepinemab + pembrolizumab | Merck | Phase 1/2 | 41 |
| Nivolumab + Paclitaxel + Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 51 |